First Patient Included in DiaGenic ASA and GE Healthcare Project to Develop a Blood Test for Mild Cognitive Impairment, Associated with Alzheimer’s

OSLO, Norway--(BUSINESS WIRE)--Regulatory News:DiaGenic ASA [OSL:DIAG] (OSE:DIAG) today announced that the first patient with MCI (Mild Cognitive Impairment) was examined with [18F] Flutemetamol PET imaging at University of Lund Sweden in the DiaGenic and GE Healthcare Research Collaboration announced March 27th 2012. First patient examined with PET imaging means that the clinical phase of the collaboration has been initiated.